Abivax
Abivax, a clinical stage biotechnology company, focuses on developing novel therapies that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases.
Abivax seeks to establish its lead drug candidate, obefazimod, as potential first-line advanced oral therapy for the treatment of inflammatory bowel diseases (IBD). This goal is based on the robust data Abivax has generated in its Phase 2 clinical trials of obefazimod in patients with moderately to severely active ulcerative colitis (UC) as well as on obefazimod’s novel mechanism of action.
Abivax is also expecting to initiate a Phase 2a clinical trial for obefazimod in Crohn’s disease (CD) and to explore the use of obefazimod as a combination therapy for the treatment of UC.
Abivax at a glance:
| Field of Activity | Abivax’s priority is the completion of its ongoing global Phase 3 clinical trials of obefazimod for the treatment of adults with moderately to severely active UC (ABTECT program). Induction and maintenance data readouts are expected in Q1 2025 and Q1 2026, respectively.
Given pathophysiological and clinical similarities of CD and UC, Abivax plans to initiate a Phase 2a trial in patients with CD in Q1 2024. |
| Ownership Structure and Financing | Abivax has been listed on the Euronext Paris since 2015 and is backed by top-tier U.S. and European investors. Abivax’s cash runway is secured through Q2 2024. |
| Partners | Abivax is conducting its ABTECT Phase 3 program with obefazimod jointly with IQVIA, a global premier contract research organization. In preparation of potential future commercialization, Abivax also plans to establish a dual source contract manufacturing organization (CMO) presence in North America to complement the existing EU CMO. |
| Technology | Obefazimod is an oral small molecule drug candidate in clinical development with a novel mechanism of action that was demonstrated to enhance the expression of a single microRNA, miR-124, which plays a critical role in the regulation of the inflammatory response. |
| Unique Selling Point | Obefazimod’s tolerability observed to date in patients with moderately to severely active UC is supported by over 1,000 patients and volunteers. Together with its convenient oral, once-daily administration, obefazimod has the potential to overcome limitations of currently available treatments and to be established as a differentiated treatment option for IBD patients. |
Contact:
| Address | 7-11 Boulevard Haussmann 75009 Paris France |
| Telephone/-fax | +33 1 53 83 09 63 |
| info@abivax.com | |
| Web Address | www.abivax.com |
| Social Media | LinkedIn Twitter |
| Date of Incorporation/ Number of Employees |
December 4, 2013/50 employees |
- Can biopharma’s drug-focused R&D strategy remain profitable?
- Abivax gibt Update zu klinischem Phase-2b-Programm
- Abivax gibt strategischen Ausblick für 2024
- A trimmed biotech basket
- "Der US-Markt hat auch tiefere Taschen"
- Abivax geht an die Nasdaq
- Advanced Therapies: Personalisierte medizinische Behandlung
- Defence Therapeutics Inc.: Will there soon be a vaccination against cancer?
- Hoffnungsträger bei chronischen Entzündungserkrankungen
- „Wer aktuell eine Finanzierung anstrebt, sollte es nicht zu eilig haben“
- Affimed präsentiert neue AFM13-Daten
- Marc de Garidel wird neuer Abivax-CEO
- Französische Abivax mit guten Phase-2b-Daten in Colitis ulcerosa - der Kurs geht nach Norden
- Abivax erhält Genehmigung für klinische COVID-19-Studie in Deutschland
- Abivax: Mit Dreifach-Wirkung gegen COVID-19
- „Wir ziehen auch die Möglichkeit eines zusätzlichen Börsengangs an die Nasdaq in Betracht“